Morningstar

argenx SE ADR ARGX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$529.95 −13.04 (2.40%)
View Full Chart
As of Delayed Price Post-Trading: $553.34 +23.38

Company Report

View Archive

Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates

Karen Andersen

Dutch biotech Argenx is hoping to build a portfolio of autoimmune treatments around Vyvgart, which received FDA approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak sales of more than $9 billion if approvals can extend into new autoimmune indications in neurology, hematology, dermatology, and nephrology over the next several years, although competitors in testing and uncertainty around future clinical trial results for Vyvgart prevent us from assigning the firm an economic moat.

Read Full Report

Price vs Fair Value

View History
ARGX is trading at a 179% premium.
Price
$543.20
Fair Value
$551.00
Uncertainty
Very High
1-Star Price
$242.76
5-Star Price
$445.50
Economic Moat
Zsv
Capital Allocation
Kpzkqglg

Bulls Say, Bears Say

Bulls

Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis and CIDP but in testing in multiple additional indications.

Bears

Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.

Show More

News

View All

Trading Information

Previous Close Price
$542.99
Day Range
$522.93–543.18
52-Week Range
$327.73–554.74
Bid/Ask
$520.00 / $553.66
Market Cap
$31.69 Bil
Volume/Avg
310,328 / 325,144

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
19.84
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,148
Website
https://www.argenx.com

Competitors

Valuation

View More
Metric
ARGX
JNJ
CSL
Price/Earnings (Normalized)
 —15.3130.03
Price/Book Value
 7.625.405.38
Price/Sales
 19.844.566.25
Price/Cash Flow
 —17.3233.21
Price/Earnings
ARGX
JNJ
CSL

Financial Strength

Metric
ARGX
JNJ
CSL
Quick Ratio
 7.520.770.87
Current Ratio
 8.531.072.18
Interest Coverage
 −229.7424.458.01
Quick Ratio
ARGX
JNJ
CSL

Profitability

Metric
ARGX
JNJ
CSL
Return on Assets (Normalized)
 −0.02%13.17%7.82%
Return on Equity (Normalized)
 −0.02%32.42%17.33%
Return on Invested Capital (Normalized)
 −3.09%20.93%10.52%
Return on Assets
ARGX
JNJ
CSL

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
NtglpgllfRgzjy$516.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
ZkbtzwbhLqpsstz$117.1 Bil
 Regeneron Pharmaceuticals Inc
REGN
RlgddsbyYdsgs$111.8 Bil
 Alnylam Pharmaceuticals Inc
ALNY
ShfqwvmNvhdkr$34.6 Bil
 BioNTech SE ADR
BNTX
TcnhlrknHcz$28.5 Bil
 Moderna Inc
MRNA
PxbjwjzBpmg$23.5 Bil
 United Therapeutics Corp
UTHR
NfsqjwvdfCbh$15.6 Bil
 Biomarin Pharmaceutical Inc
BMRN
XxvfcbvWfrqnc$13.0 Bil
 Incyte Corp
INCY
JzcbkszPyxpvn$12.9 Bil

Sponsor Center